Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Amit Sanyal, MD: A Clinician’s Perspective

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




May
09
Today In Oncology
FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma
Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants
Tiragolumab Plus Atezolizumab and Chemotherapy in Advanced Nonsquamous NSCLC
Appendiceal Cancer: Serum Tumor Marker Levels May Guide Treatment in Patients Undergoing CRS
High YAP1 Expression Leads to Chemotherapy Resistance Relapse in Treated SCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo